<p>Cerity Partners LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的股份增加了 163.9%。该公司在季度内额外收购了 45,890 股后，持有生物技术公司 73,884 股的股票。截至其最近的 SEC 文件，Cerity Partners LLC 在 Exelixis 的持股价值为 2,413,000 美元。</p>
<ul>
<li>如果有的话，3 只股票适合购买以应对软着陆</li>
</ul>
<p>其他一些对冲基金最近也调整了对 EXEL 的持股。FMR LLC 在第四季度将其在 Exelixis 的股份增加了 19.7%。FMR LLC 目前拥有 2,947,599 股生物技术公司的股票，价值 98,155,000 美元，在上个季度又购买了 485,527 股。Federated Hermes Inc. 在第四季度将其在 Exelixis 的股份增加了 82.9%。Federated Hermes Inc. 目前拥有 408,932 股生物技术公司的股票，价值 13,637,000 美元，在上个季度又购买了 185,389 股。Hurley Capital LLC 在第四季度收购了 Exelixis 的新头寸，价值约 68,000 美元。Envestnet Asset Management Inc. 在第四季度将其在 Exelixis 的头寸增加了 17.5%。Envestnet Asset Management Inc. 目前拥有 200,228 股生物技术公司的股票，价值 6,668,000 美元，在上个季度又购买了 29,892 股。最后，Grantham Mayo Van Otterloo &amp; Co. LLC 在第四季度将其在 Exelixis 的股份增加了 80.2%。Grantham Mayo Van Otterloo &amp; Co. LLC 目前拥有 151,153 股生物技术公司的股票，价值 5,033,000 美元，在上个季度又收购了 67,256 股。机构投资者持有该公司 85.27% 的股票。</p>
<h2>Exelixis 的内部交易</h2>
<p>在其他新闻中，董事 Jack L. Wyszomierski 于 2 月 28 日星期五出售了 8,768 股 Exelixis 股票。该股票以平均价格 37.80 美元出售，总价值为 331,430.40 美元。交易后，该董事现在持有 356,605 股公司股票，价值约 13,479,669 美元。此次交易使其持股减少了 2.40%。该交易已在向证券交易委员会的文件中披露，可以通过此超链接访问。此外，执行副总裁 Patrick J. Haley 于 2 月 24 日星期一出售了 52,636 股该股票。该股票以平均价格 36.98 美元出售，总价值为 1,946,479.28 美元。出售后，该执行副总裁现在持有 303,310 股公司股票，价值 11,216,403.80 美元。这代表其持股减少了 14.79%。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了价值 5,177,234 美元的 140,343 股公司股票。当前内部人士持有 2.85% 的股票。</p>
<h2>分析师的升级和降级</h2>
<ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
<p>几位股票分析师对 EXEL 股票发布了报告。JMP Securities 在 1 月 23 日的研究报告中重申了 &#34;市场表现优于大盘&#34; 的评级，并对 Exelixis 股票设定了 41.00 美元的目标价。Guggenheim 在 2 月 12 日的研究报告中重申了 &#34;买入&#34; 的评级，并对 Exelixis 股票设定了 42.00 美元的目标价。Stifel Nicolaus 在 2 月 12 日的报告中将 Exelixis 的目标价从 30.00 美元上调至 36.00 美元，并给予该股票 &#34;持有&#34; 的评级。摩根士丹利在 1 月 27 日的报告中将 Exelixis 的评级从 &#34;持平&#34; 上调至 &#34;超配&#34;，并将该股票的目标价从 30.00 美元上调至 40.00 美元。最后，美国银行在 12 月 17 日的研究报告中将 Exelixis 的评级从 &#34;买入&#34; 下调至 &#34;中性&#34;，并将该公司的目标价从 35.00 美元上调至 39.00 美元。一位分析师对该股票给予了卖出评级，八位分析师给予了持有评级，十一位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，平均目标价为 37.59 美元。</p>
<p><strong>查看我们对 Exelixis 的最新分析</strong></p>
<h2>Exelixis 股票上涨 2.2%</h2>
<ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
<p>NASDAQ EXEL 周三开盘价为 36.54 美元。该股票的 50 日简单移动平均线为 36.26 美元，200 日简单移动平均线为 34.09 美元。Exelixis, Inc. 的 12 个月低点为 20.14 美元，12 个月高点为 40.02 美元。该公司的市值为 102.3 亿美元，市盈率为 20.64，PEG 比率为 1.13，贝塔值为 0.57。</p>
<p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 2 月 11 日宣布了其季度财报。这家生物技术公司报告该季度每股收益为 0.48 美元，低于分析师的共识预期 0.51 美元，差距为 0.03 美元。Exelixis 的净利润率为 24.04%，股本回报率为 23.52%。平均而言，股票分析师预计 Exelixis, Inc. 在当前财政年度将发布每股收益 2.04 美元。</p>
<h2>Exelixis 公司简介</h2>
<p>（免费报告）</p>
<p>Exelixis, Inc. 是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票超过 Exelixis</li>
<li>WallStreetBets 是什么，它们针对哪些股票？</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>选举股票：选举如何影响股市</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>成长股：它们是什么，它们又不是？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
<p><strong>想知道其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Exelixis, Inc. (NASDAQ:EXEL - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
<p>在考虑 Exelixis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Exelixis 并不在名单上。</p>
<p>虽然 Exelixis 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

伊克力西斯

<p>Cerity Partners LLC 在第四季度将其在 Exelixis, Inc. (NASDAQ:EXEL) 的持股增加了 163.9%，额外购买了 45,890 股，总持股达到 73,884 股，价值 241 万美元。其他对冲基金也增加了他们的持股。内部交易包括董事 Jack L. Wyszomierski 和执行副总裁 Patrick J. Haley 的出售。分析师对 EXEL 的评级褒贬不一，普遍评级为 “适度买入”，平均目标价为 37.59 美元。Exelixis 股票开盘价为 36.54 美元，市值为 102.3 亿美元</p>

<p>Cerity Partners LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 163.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 73,884 shares of the biotechnology company's stock after acquiring an additional 45,890 shares during the quarter. Cerity Partners LLC's holdings in Exelixis were worth $2,413,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Cerity Partners LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度将其在 Exelixis, Inc.（NASDAQ:EXEL - 免费报告）的股份增加了 163.9%。该公司在季度内额外收购了 45,890 股后，持有生物技术公司 73,884 股的股票。截至其最近的 SEC 文件，Cerity Partners LLC 在 Exelixis 的持股价值为 2,413,000 美元。</p>
</div><ul>
<li>3 Stocks to Buy for a Soft Landing, If There Is One</li>
</ul>
<div class="lb-trans"><ul>
<li>如果有的话，3 只股票适合购买以应对软着陆</li>
</ul>
</div><p>A number of other hedge funds also recently modified their holdings of EXEL. FMR LLC grew its stake in Exelixis by 19.7% during the fourth quarter. FMR LLC now owns 2,947,599 shares of the biotechnology company's stock worth $98,155,000 after buying an additional 485,527 shares in the last quarter. Federated Hermes Inc. increased its stake in shares of Exelixis by 82.9% in the 4th quarter. Federated Hermes Inc. now owns 408,932 shares of the biotechnology company's stock valued at $13,637,000 after purchasing an additional 185,389 shares during the last quarter. Hurley Capital LLC acquired a new position in Exelixis during the fourth quarter worth about $68,000. Envestnet Asset Management Inc. increased its position in Exelixis by 17.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 200,228 shares of the biotechnology company's stock worth $6,668,000 after purchasing an additional 29,892 shares in the last quarter. Finally, Grantham Mayo Van Otterloo &amp; Co. LLC lifted its stake in shares of Exelixis by 80.2% in the 4th quarter. Grantham Mayo Van Otterloo &amp; Co. LLC now owns 151,153 shares of the biotechnology company's stock valued at $5,033,000 after acquiring an additional 67,256 shares during the last quarter. Institutional investors own 85.27% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也调整了对 EXEL 的持股。FMR LLC 在第四季度将其在 Exelixis 的股份增加了 19.7%。FMR LLC 目前拥有 2,947,599 股生物技术公司的股票，价值 98,155,000 美元，在上个季度又购买了 485,527 股。Federated Hermes Inc. 在第四季度将其在 Exelixis 的股份增加了 82.9%。Federated Hermes Inc. 目前拥有 408,932 股生物技术公司的股票，价值 13,637,000 美元，在上个季度又购买了 185,389 股。Hurley Capital LLC 在第四季度收购了 Exelixis 的新头寸，价值约 68,000 美元。Envestnet Asset Management Inc. 在第四季度将其在 Exelixis 的头寸增加了 17.5%。Envestnet Asset Management Inc. 目前拥有 200,228 股生物技术公司的股票，价值 6,668,000 美元，在上个季度又购买了 29,892 股。最后，Grantham Mayo Van Otterloo &amp; Co. LLC 在第四季度将其在 Exelixis 的股份增加了 80.2%。Grantham Mayo Van Otterloo &amp; Co. LLC 目前拥有 151,153 股生物技术公司的股票，价值 5,033,000 美元，在上个季度又收购了 67,256 股。机构投资者持有该公司 85.27% 的股票。</p>
</div><h2>Insider Transactions at Exelixis</h2>
<div class="lb-trans"><h2>Exelixis 的内部交易</h2>
</div><p>In other news, Director Jack L. Wyszomierski sold 8,768 shares of Exelixis stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the transaction, the director now owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jack L. Wyszomierski 于 2 月 28 日星期五出售了 8,768 股 Exelixis 股票。该股票以平均价格 37.80 美元出售，总价值为 331,430.40 美元。交易后，该董事现在持有 356,605 股公司股票，价值约 13,479,669 美元。此次交易使其持股减少了 2.40%。该交易已在向证券交易委员会的文件中披露，可以通过此超链接访问。此外，执行副总裁 Patrick J. Haley 于 2 月 24 日星期一出售了 52,636 股该股票。该股票以平均价格 36.98 美元出售，总价值为 1,946,479.28 美元。出售后，该执行副总裁现在持有 303,310 股公司股票，价值 11,216,403.80 美元。这代表其持股减少了 14.79%。该销售的披露信息可以在这里找到。在过去的九十天里，内部人士出售了价值 5,177,234 美元的 140,343 股公司股票。当前内部人士持有 2.85% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><ul>
<li>3 Strong Biotech Performers To Watch As Sector Nears Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只强劲的生物技术股票值得关注，随着行业接近突破</li>
</ul>
</div><p>Several equities analysts have issued reports on EXEL shares. JMP Securities restated a &#34;market outperform&#34; rating and issued a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. Guggenheim restated a &#34;buy&#34; rating and set a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Stifel Nicolaus lifted their target price on Exelixis from $30.00 to $36.00 and gave the stock a &#34;hold&#34; rating in a report on Wednesday, February 12th. Morgan Stanley upgraded Exelixis from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their price target for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Finally, Bank of America lowered Exelixis from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and boosted their target price for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $37.59.</p>
<div class="lb-trans"><p>几位股票分析师对 EXEL 股票发布了报告。JMP Securities 在 1 月 23 日的研究报告中重申了 &#34;市场表现优于大盘&#34; 的评级，并对 Exelixis 股票设定了 41.00 美元的目标价。Guggenheim 在 2 月 12 日的研究报告中重申了 &#34;买入&#34; 的评级，并对 Exelixis 股票设定了 42.00 美元的目标价。Stifel Nicolaus 在 2 月 12 日的报告中将 Exelixis 的目标价从 30.00 美元上调至 36.00 美元，并给予该股票 &#34;持有&#34; 的评级。摩根士丹利在 1 月 27 日的报告中将 Exelixis 的评级从 &#34;持平&#34; 上调至 &#34;超配&#34;，并将该股票的目标价从 30.00 美元上调至 40.00 美元。最后，美国银行在 12 月 17 日的研究报告中将 Exelixis 的评级从 &#34;买入&#34; 下调至 &#34;中性&#34;，并将该公司的目标价从 35.00 美元上调至 39.00 美元。一位分析师对该股票给予了卖出评级，八位分析师给予了持有评级，十一位分析师给予了买入评级，还有一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，平均目标价为 37.59 美元。</p>
</div><p><strong>View Our Latest Analysis on Exelixis</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Exelixis 的最新分析</strong></p>
</div><h2>Exelixis Stock Up 2.2 %</h2>
<div class="lb-trans"><h2>Exelixis 股票上涨 2.2%</h2>
</div><ul>
<li>7 Best Cancer Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>现在投资的 7 只最佳癌症股票</li>
</ul>
</div><p>NASDAQ EXEL opened at $36.54 on Wednesday. The stock's 50-day simple moving average is $36.26 and its two-hundred day simple moving average is $34.09. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The company has a market capitalization of $10.23 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.13 and a beta of 0.57.</p>
<div class="lb-trans"><p>NASDAQ EXEL 周三开盘价为 36.54 美元。该股票的 50 日简单移动平均线为 36.26 美元，200 日简单移动平均线为 34.09 美元。Exelixis, Inc. 的 12 个月低点为 20.14 美元，12 个月高点为 40.02 美元。该公司的市值为 102.3 亿美元，市盈率为 20.64，PEG 比率为 1.13，贝塔值为 0.57。</p>
</div><p>Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Exelixis（NASDAQ:EXEL - 获取免费报告）最近于 2 月 11 日宣布了其季度财报。这家生物技术公司报告该季度每股收益为 0.48 美元，低于分析师的共识预期 0.51 美元，差距为 0.03 美元。Exelixis 的净利润率为 24.04%，股本回报率为 23.52%。平均而言，股票分析师预计 Exelixis, Inc. 在当前财政年度将发布每股收益 2.04 美元。</p>
</div><h2>Exelixis Company Profile</h2>
<div class="lb-trans"><h2>Exelixis 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.</p>
<div class="lb-trans"><p>Exelixis, Inc. 是一家肿瘤学公司，专注于在美国发现、开发和商业化用于治疗难治性癌症的新药。该公司提供 CABOMETYX 片剂，用于治疗接受过抗血管生成治疗的晚期肾细胞癌患者；以及 COMETRIQ 胶囊，用于治疗进展性和转移性髓样甲状腺癌。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Exelixis</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Growth Stocks: What They Are, What They Are Not</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Exelixis</li>
<li>WallStreetBets 是什么，它们针对哪些股票？</li>
<li>小心 BigBear.ai：内部人士正在出售——你应该吗？</li>
<li>选举股票：选举如何影响股市</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>成长股：它们是什么，它们又不是？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding EXEL?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 EXEL 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Exelixis, Inc. (NASDAQ:EXEL - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhFTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EXEL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Exelixis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Exelixis 吗？</h2>
</div><p>Before you consider Exelixis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Exelixis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Exelixis 并不在名单上。</p>
</div><p>While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Exelixis 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cerity Partners LLC 购入了 45,890 股伊克力西斯公司（纳斯达克股票代码：EXEL）